Galectin Therapeutics Inc. (GALT) Forecasted to Post FY2017 Earnings of ($1.09) Per Share
Galectin Therapeutics Inc. (NASDAQ:GALT) – Investment analysts at FBR & Co cut their FY2017 earnings per share estimates for shares of Galectin Therapeutics in a research note issued on Monday. FBR & Co analyst V. Bernardino now expects that the firm will earn ($1.09) per share for the year, down from their prior estimate of $0.50. FBR & Co currently has a “Market Perform” rating and a $2.00 target price on the stock. FBR & Co also issued estimates for Galectin Therapeutics’ FY2018 earnings at ($0.71) EPS, FY2019 earnings at ($0.88) EPS and FY2020 earnings at ($0.50) EPS.
GALT has been the topic of a number of other research reports. Zacks Investment Research upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Galectin Therapeutics in a report on Thursday, August 4th. Finally, Roth Capital restated a “sell” rating and issued a $0.75 price objective (down previously from $3.00) on shares of Galectin Therapeutics in a report on Wednesday, September 28th.
Shares of Galectin Therapeutics (NASDAQ:GALT) traded down 2.9604% during mid-day trading on Wednesday, hitting $0.9801. 214,813 shares of the company were exchanged. The stock’s 50-day moving average price is $1.77 and its 200 day moving average price is $1.60. Galectin Therapeutics has a 12-month low of $0.94 and a 12-month high of $3.25. The stock’s market cap is $28.70 million.
Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04.
Large investors have recently made changes to their positions in the company. BlackRock Fund Advisors boosted its stake in shares of Galectin Therapeutics by 33.8% in the second quarter. BlackRock Fund Advisors now owns 78,955 shares of the company’s stock worth $116,000 after buying an additional 19,967 shares during the last quarter. Advisor Group Inc. bought a new stake in shares of Galectin Therapeutics during the second quarter worth about $584,000. Finally, Vanguard Group Inc. boosted its stake in shares of Galectin Therapeutics by 0.4% in the second quarter. Vanguard Group Inc. now owns 606,537 shares of the company’s stock worth $892,000 after buying an additional 2,490 shares during the last quarter. 11.69% of the stock is owned by hedge funds and other institutional investors.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Stock Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related stocks with our FREE daily email newsletter.